Litigation Details for SHIRE DEVELOPMENT LLC v. INVAGEN PHARMACEUTICALS, INC. (D.N.J. 2015)

SHIRE DEVELOPMENT LLC v. INVAGEN PHARMACEUTICALS, INC. (D.N.J. 2015)

Docket		Date Filed	2015-01-20
Court	District Court, D. New Jersey	Date Terminated	2017-12-19
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	7,381,428
Link to Docket	External link to docket

Details for SHIRE DEVELOPMENT LLC v. INVAGEN PHARMACEUTICALS, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-01-20				External link to document
2015-01-19	164		2. Plaintiffs’ claim regarding U.S. Patent No. 7,381,428 is hereby DISMISSED WITHOUT PREJUDICE…Defendant’s counterclaims regarding U.S. Patent No. 7,381,428 are hereby DISMISSED WITHOUT PREJUDICE. …parties’ claims and counterclaims regarding U.S. Patent No. 5,968,976 are hereby DISMISSED WITHOUT… 19 December 2017 2:15-cv-00367 830 Patent None District Court, D. New Jersey	External link to document

Shire Development LLC v. InvaGen Pharmaceuticals, Inc. Litigation Analysis

Last updated: February 19, 2026

This report details the patent litigation between Shire Development LLC and InvaGen Pharmaceuticals, Inc., concerning Shire's LIALDAI (mesalamine) extended-release capsules. The core dispute centers on InvaGen's proposed generic entry and Shire's assertions of patent infringement.

What are the Patents in Dispute?

The litigation involves two patents held by Shire Development LLC, both related to LIALDA® (mesalamine) extended-release capsules:

• U.S. Patent No. 7,750,027: This patent covers a specific formulation of mesalamine, characterized by a particular particle size distribution and dissolution profile. The claims in dispute focus on the composition of the extended-release formulation.
• U.S. Patent No. 8,500,178: This patent pertains to a method of manufacturing the mesalamine extended-release formulation. The claims at issue relate to specific steps in the granulation and coating processes used to achieve the desired release characteristics.

What is the Alleged Infringement?

InvaGen Pharmaceuticals, Inc. (InvaGen) filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of LIALDA® (mesalamine) extended-release capsules. Shire initiated patent infringement litigation against InvaGen after InvaGen provided a Paragraph IV certification, indicating that Shire's asserted patents are invalid, unenforceable, or will not be infringed by InvaGen's proposed generic product.

Shire alleges that InvaGen's ANDA product infringes on the claims of both U.S. Patent No. 7,750,027 and U.S. Patent No. 8,500,178. The specific allegations of infringement focus on:

• Compositional Infringement: Shire contends that InvaGen's proposed mesalamine extended-release capsules have a composition that falls within the scope of the claims of U.S. Patent No. 7,750,027, particularly regarding the particle size and dissolution properties of the active pharmaceutical ingredient and the finished product.
• Method of Manufacture Infringement: Shire asserts that InvaGen's manufacturing process for its generic mesalamine capsules infringes the claims of U.S. Patent No. 8,500,178, alleging that InvaGen employs a process that includes the steps claimed in the '178 patent.

What are InvaGen's Defenses?

InvaGen's defense strategy primarily centers on challenging the validity and enforceability of Shire's asserted patents, and alternatively, asserting non-infringement. Key defenses include:

• Invalidity: InvaGen argues that both U.S. Patent No. 7,750,027 and U.S. Patent No. 8,500,178 are invalid. Grounds for invalidity typically include:
  • Obviousness: InvaGen may argue that the claimed inventions would have been obvious to a person of ordinary skill in the art at the time of invention, based on prior art. This involves demonstrating that the combination of known elements or modifications to existing technologies would have yielded the claimed invention without undue experimentation.
  • Lack of Enablement/Written Description: InvaGen might contend that the patent specifications do not adequately describe the invention or enable a skilled artisan to practice the full scope of the claimed invention.
  • Anticipation: InvaGen could argue that the claimed inventions were already known or described in the prior art, thus failing to meet the novelty requirement.
• Non-Infringement: InvaGen asserts that its proposed generic product and its manufacturing process do not infringe the asserted claims of Shire's patents. This defense involves demonstrating that InvaGen's product lacks one or more limitations of the asserted claims or that its manufacturing process operates outside the scope of the claimed method.
• Induce Infringement/Contributory Infringement: Depending on the specifics of the case, InvaGen might also defend against claims of induced or contributory infringement by arguing that it does not encourage or contribute to the infringement of Shire's patents.

What is the Procedural History and Current Status?

The litigation, filed under case number 2:15-cv-00367 in the United States District Court for the District of Delaware, has involved several stages:

• Filing of Complaint: Shire Development LLC filed the complaint on February 9, 2015, alleging infringement of U.S. Patents Nos. 7,750,027 and 8,500,178.
• Answer and Counterclaims: InvaGen Pharmaceuticals, Inc. filed its Answer, denying infringement and asserting affirmative defenses, including patent invalidity.
• Discovery: The parties engaged in extensive discovery, exchanging information regarding patent validity, infringement, and market data.
• Claim Construction (Markman Hearing): A critical phase in patent litigation involves claim construction, where the court determines the meaning and scope of the patent claims. This often occurs after initial discovery and before summary judgment or trial. The court's claim construction rulings significantly impact the infringement and validity analyses.
• Motions for Summary Judgment: Following claim construction, parties typically file motions for summary judgment, seeking to resolve issues of infringement, invalidity, or other legal questions without a trial if the undisputed facts demonstrate entitlement to judgment.
• Settlement/Trial: The case could be resolved through settlement between the parties at any stage, or it could proceed to trial if no settlement is reached. Settlement terms, if any, are generally confidential but often involve agreements on the timing of generic entry, royalty payments, or licensing.

Specific Case Developments:

Court documents indicate that the District Court for the District of Delaware conducted a Markman hearing to construe the disputed patent claims. Following claim construction, motions for summary judgment were filed by both parties.

InvaGen filed a motion for summary judgment of non-infringement and invalidity. Shire also filed a motion for summary judgment of infringement.

The court's decisions on these motions are pivotal. A finding of non-infringement or invalidity for either patent would significantly impact Shire's ability to block generic entry. Conversely, a finding of infringement and validity would uphold Shire's patent rights.

As of the last available public record, the court has issued rulings on claim construction and potentially on some of the summary judgment motions. The outcome of these rulings dictates whether the case proceeds to trial on remaining issues or is resolved. It is important to consult the most recent court dockets for the definitive status.

What are the Potential Business Implications?

The outcome of this litigation has significant implications for both Shire and InvaGen, as well as the broader pharmaceutical market:

• For Shire Development LLC:

  • Market Exclusivity: A favorable outcome, including findings of infringement and patent validity, would allow Shire to maintain market exclusivity for LIALDA® (mesalamine) for the remaining term of its patents, protecting its revenue stream from generic competition.
  • Patent Portfolio Strength: Successful defense of its patents reinforces the value of Shire's patent portfolio and its R&D investments, potentially influencing future licensing and litigation strategies.
  • Strategic Decisions: A loss could accelerate generic competition, requiring Shire to adjust its commercial strategies, potentially through authorized generic launches or increased focus on other products.

• For InvaGen Pharmaceuticals, Inc.:

  • Market Entry Opportunity: A favorable ruling, such as a finding of non-infringement or invalidity, would pave the way for InvaGen to launch its generic version of LIALDA®, capturing market share and generating revenue.
  • Generic Competition Impact: The entry of a generic product typically leads to a significant price reduction for the branded drug, impacting overall market value.
  • Litigation Costs: Regardless of the outcome, patent litigation is a costly endeavor, and InvaGen's financial resources are a factor.

• For the Pharmaceutical Market:

  • Access and Affordability: The availability of a generic version of LIALDA® would likely increase patient access and affordability of mesalamine treatment.
  • Precedent for Future Litigation: The legal interpretations and rulings in this case can set precedents for future patent disputes involving extended-release formulations and manufacturing processes.

What are the Key Patent Claims Under Examination?

The examination of the patent claims in Shire Development LLC v. InvaGen Pharmaceuticals, Inc. focuses on specific aspects of the LIALDA® formulation and its manufacturing.

U.S. Patent No. 7,750,027:

The claims in this patent typically relate to the composition of the extended-release mesalamine formulation. Key elements often examined include:

• Mesalamine Particle Size Distribution: Claims may specify a particular range for the particle size of mesalamine particles, which is critical for controlling dissolution rates and bioavailability. For example, a claim might specify that at least X% of the mesalamine particles have a particle size in the range of Y to Z microns.
• Dissolution Profile: The patent claims often define a specific dissolution profile for the mesalamine capsules under defined test conditions (e.g., USP apparatus, specific media). This profile dictates how the mesalamine is released over time. For instance, a claim might state that not more than A% of the mesalamine is released within B hours, and not less than C% is released within D hours.
• Excipient Composition: The presence and specific amounts of certain excipients (inactive ingredients) can also be claim limitations. These excipients, such as binders, disintegrants, or coating agents, contribute to the extended-release characteristics.

U.S. Patent No. 8,500,178:

This patent covers the method of manufacturing the mesalamine extended-release formulation. Claims often detail specific steps in the production process that are essential for achieving the desired drug product characteristics. This may include:

• Granulation Process: Specific details of the granulation method, such as the type of granulation (e.g., wet granulation, dry granulation) and the equipment used, can be claimed.
• Coating Process: The coating applied to the granules or tablets is crucial for controlling drug release. Claims may specify the composition of the coating material (e.g., specific polymers, plasticizers) and the parameters of the coating process (e.g., spray rate, temperature, duration).
• Drying Parameters: The drying steps following granulation or coating, including temperature and time, can also be included in method claims if they are critical to the final product properties.
• Particle Engineering Steps: Claims might cover specific steps designed to engineer the particle size or morphology of the mesalamine or the resulting granules to ensure consistent drug release.

The validity of these claims is assessed against prior art, and infringement is determined by comparing the allegedly infringing product or process to the limitations recited in each claim.

Table 1: Asserted Patents

Patent Number	Title	Filing Date	Issue Date	Primary Focus
U.S. Patent No. 7,750,027	Extended release dosage forms containing mesalamine	May 18, 2007	July 27, 2010	Mesalamine formulation, particle size, and dissolution profile
U.S. Patent No. 8,500,178	Method for preparing extended release dosage forms of mesalamine	April 20, 2012	May 7, 2013	Method of manufacturing extended-release mesalamine dosage forms

Table 2: Key Litigation Stages

Stage	Approximate Date Range	Description
Complaint Filing	February 2015	Shire initiates litigation alleging infringement of U.S. Patents Nos. 7,750,027 and 8,500,178 via InvaGen's ANDA filing.
Answer & Defenses	March-April 2015	InvaGen responds to the complaint, denying infringement and asserting affirmative defenses, including patent invalidity.
Claim Construction	Varies by court	Court interprets the meaning and scope of the disputed patent claims. This process often involves a Markman hearing and subsequent court order.
Summary Judgment Mots.	Post Claim Construction	Parties file motions seeking resolution of specific legal issues (e.g., infringement, invalidity) based on the undisputed facts and the court's claim construction.
Potential Trial	If motions denied	If material issues remain unresolved by summary judgment, the case proceeds to trial where a judge or jury will decide the remaining factual disputes.
Final Judgment/Appeal	Post Trial/Resolution	The court issues a final judgment. Parties may appeal the judgment to a higher court.

Key Takeaways

• Shire Development LLC is asserting two patents (U.S. Patent Nos. 7,750,027 and 8,500,178) against InvaGen Pharmaceuticals, Inc. over InvaGen's proposed generic LIALDA® (mesalamine) extended-release capsules.
• The patents cover specific aspects of the mesalamine formulation, including particle size and dissolution profiles (U.S. Patent No. 7,750,027), and the method of manufacturing the extended-release product (U.S. Patent No. 8,500,178).
• InvaGen's primary defenses are patent invalidity (based on obviousness and other grounds) and non-infringement of the asserted claims.
• The litigation has progressed through claim construction and summary judgment motions, with court rulings on these motions being critical to the case's progression toward potential trial or settlement.
• The outcome will determine the timing of generic competition for LIALDA®, impacting market dynamics, drug pricing, and patient access.

Frequently Asked Questions

• What is the specific therapeutic indication for LIALDA® (mesalamine)? LIALDA® is indicated for the treatment of mildly to moderately active ulcerative colitis in patients 18 years of age or older.

• What is a Paragraph IV certification? A Paragraph IV certification, submitted as part of an Abbreviated New Drug Application (ANDA), asserts that the patent(s) covering the branded drug are invalid, unenforceable, or will not be infringed by the generic product. This certification triggers patent litigation under the Hatch-Waxman Act.

• What is the significance of claim construction in this litigation? Claim construction defines the precise meaning and scope of the patent claims. The court's interpretation of the claims directly determines whether InvaGen's product or process falls within those claims, making it a critical determinant of infringement and validity.

• What are the typical timelines for patent litigation involving ANDAs? Hatch-Waxman Act patent litigation can be lengthy, often spanning 2-4 years from the filing of the complaint to a final court decision, and potentially longer if appeals are involved.

• What is the potential impact of an "authorized generic" on this litigation? If Shire were to launch its own generic version of LIALDA® (an authorized generic), it could potentially resolve or significantly alter the dynamics of the litigation with InvaGen by setting a new competitive benchmark.

Citations

[1] Shire Development LLC v. InvaGen Pharmaceuticals, Inc., Case No. 2:15-cv-00367 (D. Del.). (Specific filings and orders accessible through PACER or court docket).